Zai Lab: Revenue Growth And Zoci's Upside Optionality

Impact · against what's priced in

Zai Lab presents a positive outlook driven by revenue stabilization and clinical optionality for Zoci, though its high valuation multiple limits the immediate upside. The shift toward a proprietary global pipeline provides long-term growth potential that may justify its current premium.

ZLAB+0.40

No priced-in read yet

In context

The expectation for product sales to stabilize in 2H2026 and the promising clinical activity for Zoci in SCLC and NEC provide catalysts, though high valuation multiples compared to peers act as a drag.

Read from the article alone

• healthcare
• ZLAB
• biopharma
• china
• clinical trials
• immunology
• oncology
• pipeline

Search tags